Partnership / Collaboration · GCC · Announced 28 Apr 2026
Fosun Pharma → Arcera Life Sciences
Fosun Pharma and ADQ-backed Arcera Life Sciences signed an MoU for a long-term collaboration covering licensing of Fosun assets, possible UAE biotech joint ventures and neuroscience research.
Parties: Fosun Pharma (China) → Arcera Life Sciences (United Arab Emirates)
- Deal type
- Partnership / Collaboration
- Value
- Undisclosed
- Territory
- UAE (Abu Dhabi) and China; patient access across the Middle East and beyond
- Therapeutic area
- Multi-therapy
- Assets
- Oncology assets; Neuroscience assets; Rare disease assets; Cardiometabolic assets
- Announced
- 28 Apr 2026
Our analysis
Why this matters
On 28 April 2026, Shanghai Fosun Pharmaceutical Group and Abu Dhabi-based Arcera Life Sciences signed a memorandum of understanding establishing a long-term strategic collaboration. It covers three areas: regional and global licensing of assets, starting with Fosun compounds in oncology, neuroscience, rare diseases and cardiometabolic disease that are in advanced development or on the market in China; incubation of frontier technologies, including possible joint ventures or new entities to localise biotechnology in the UAE across small molecules, biologics, radiopharmaceuticals, siRNA and cell and gene therapies; and neuroscience, with a focus on neurodegenerative diseases including Alzheimer's. No values or timelines were disclosed. Arcera's CEO called it the company's first strategic partnership.
The companies linked the deal to the China–UAE Comprehensive Strategic Partnership and Abu Dhabi's Healthcare Life Sciences Vision 2030.
The full analysis is free to read with a work email on this page.
Source: PR Newswire (joint release)